Antivirulence agent having indolidone group and use thereof

Indolidone-based antivirulence agents target Staphylococcus aureus virulence factors, addressing antibiotic resistance by inhibiting bacterial virulence without killing the bacteria, thus providing an effective and resistance-free treatment for infections.

WO2025173908A1 Publication Date: 2025-08-21RES & BUSINESS FOUND SUNGKYUNKWAN UNIV +1
2 Cites 0 Cited by

Patent Information

Application Number
PCT/KR2024/095298
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Filing Date
2024-02-16
Publication Date
2025-08-21

AI Technical Summary

Technical Problem

The emergence of antibiotic-resistant bacteria has led to a rise in untreatable infections, necessitating the development of new treatments that can inhibit bacterial virulence without killing the bacteria, as traditional antibiotics contribute to the development of resistance.

Method used

Development of antivirulence agents, specifically compounds with an indolidone group, such as HM12 and its derivatives, which target and inhibit key virulence factors in Staphylococcus aureus by interfering with two-component systems like AgrC and SaeS, reducing the expression of virulence genes without inducing resistance.

Benefits of technology

The indolidone-based compounds effectively suppress bacterial toxicity, reduce the risk of resistance development, and minimize adverse effects on the human microbiota, offering a promising alternative to traditional antibiotics for treating Staphylococcus aureus infections.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention relates to an antivirulence agent having an indolidone group and a use thereof. More specifically, the present invention relates to an antivirulence agent against Staphylococcus aureus, the agent being a compound having an indolidone group, and a pharmaceutical composition for treating Staphylococcus aureus infection. The compound having an indolidone group according to the present invention has excellent antivirulence activity that inhibits bacterial virulence without inducing bacterial resistance, and thus can be effectively used as an antivirulence agent for bacteria and a therapeutic agent for bacterial infections.
Need to check novelty before this filing date? Find Prior Art